STAAR Surgical Co

STAAR Surgical Co has a market capitalization of $1.62 billion and a price-to-book ratio of 4.72, indicating a premium valuation relative to its book value. The company holds $153.15 million in cash and equivalents, with no long-term debt, and a current ratio of 4.55, suggesting strong short-term liquidity. However, its operating cash flow is negative at -$34.23 million, and free cash flow is -$77.54 million, reflecting ongoing cash outflows from operations. The company reported a net loss of $80.45 million and an operating loss of $91.71 million, with a return on equity of -23.37% and a return on assets of -17.81%, both significantly below industry norms for medical equipment firms. Gross profit of $182.42 million represents 76.2% of revenue, but the company's inability to convert this into operating profit highlights operational inefficiencies or cost overruns. STAAR Surgical Co generates all of its revenue from a single business segment focused on intraocular lenses and related products, with no geographic diversification disclosed in the latest financials. This concentration increases exposure to market-specific risks, such as regulatory changes or shifts in surgical procedure volumes. The company's revenue for the latest period was $239.44 million, with no growth trajectory disclosed in the outlook. Analysts have assigned a mean price target of $21.11, significantly below the current market price of $32.79, suggesting a bearish consensus. The absence of guidance for the next fiscal year and the lack of capital expenditure plans indicate a conservative or stagnant growth strategy. Risk factors include a low liquidity score and a negative operating cash flow, which could constrain the company's ability to fund operations or invest in growth. The dilution risk is currently low, with no immediate filing-based flags detected, and shares outstanding remain unchanged between basic and diluted counts. Recent filings and transcripts do not disclose any material events or strategic shifts, and the company has not issued new shares or announced significant capital raises in the latest period. Analysts have issued 2 "Buy" and 9 "Hold" ratings, with no "Strong Buy" recommendations, reflecting a cautious outlook.